Benchmarking open-source tools for in silico antiviral drug discovery

Daniel C. Elton; Preston W. Estep

Home/Archive/arXiv

arXiv · 2605.04265

Benchmarking open-source tools for in silico antiviral drug discovery

Daniel C. Elton·Preston W. Estep

View original source ↗Read source document ↗Export metadata ↓

Abstract

Antivirals are uniquely positioned to be deployed quickly during a new outbreak, especially when repurposed from approved drugs. Yet there are no FDA-approved antivirals for the majority of viral families with pandemic potential. Here we lay out the case for investing in technologies and techniques for antiviral drug discovery and designing antiviral combinations. We present a survey of open source datasets and computational tools for in silico antiviral drug discovery, with a particular focus on the latest AI-based systems and docking tools. We then present our custom dataset of 43,005 viral protein-ligand binding measurements that we curated from BindingDB and other sources. Importantly, we found that 31% of viral protein binding data in BindingDB required polyprotein sequences to be carefully split before the data were suitable for training or testing ML models. Using our custom dataset we fine-tuned the DrugFormDTA binding affinity prediction model (Khokhlov et al. 2025). We then benchmarked 15 open-source binding affinity prediction tools on a custom test set of 853 antiviral compounds spread across 16 different protein targets from 10 virus species. Models tested include Boltz-2, GNINA, FlowDock, Interformer, AutoDock-GPU, and others. We found that Boltz-2 and DrugFormDTA ranked highest overall among ML-based approaches, and GNINA did best among docking approaches, with notable variance across specific viral proteins. Fine-tuning DrugFormDTA on our custom cleaned antiviral dataset boosted performance from $r=0.5$ to $r=0.7$. As part of this work we also compiled a library of approved drugs and a comprehensive list of investigational and approved antiviral drugs that can be viewed at https://antivirals-database.radvac.org. Together, this work provides a foundation for future work towards new tools and platforms for rapid drug repurposing and rapid design of antiviral combinations.

Explore related subjects

q-bio.BM q-bio.QM

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Daniel C. Elton, Preston W. Estep. 2026-05-05. Benchmarking open-source tools for in silico antiviral drug discovery. https://arxiv.org/abs/2605.04265

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related papers

arXiv2026

In Vivo Length Distributions as Mechanistic Fingerprints of Pathological Protein Aggregation

Modern imaging techniques can resolve individual pathological protein aggregates in postmortem human samples, providing detailed measurements of aggregate size distributions that are inaccessible with conventional bulk approaches. These distributions represent mechanistic fingerprints of the microscopic processes that generated the observed pathology, but extracting this mechanistic information requires a quantitative theoretical framework. Here, we develop the mathematical tools needed to interpret aggregate length distributions in living systems, where aggregate growth competes with active removal. We show that, across a class of models, the length distribution of sufficiently large aggregates approaches a geometric decay. Crucially, the decay rate is determined by the balance between aggregate elongation and removal, providing a direct quantitative readout of these competing processes from a single time point measurement. This enables mechanistic comparisons between healthy and diseased human samples without requiring longitudinal measurements of aggregate dynamics. We further analyse how additional aggregation and removal processes modify the observed length distributions. Together, these results establish the mathematical foundations and tools to use aggregate length distributions as an experimentally accessible route for inferring microscopic aggregation dynamics directly from human tissue.

q-bio.BM↗

arXiv2026

Decoding enzyme-substrate interaction topology reveals principles underlying catalytic efficiency and mutational outcomes

The enzyme turnover number (kcat) defines catalytic efficiency and constrains quantitative models of metabolism, yet the molecular determinants governing kcat and its response to mutation remain poorly understood. Measurements are sparse and labor-intensive, and most computational approaches provide numerical predictions without explaining how enzyme-substrate interactions shape catalytic outcomes. A central challenge is therefore to identify the topological principles that determine where mutations act and how their functional outcomes are encoded within the enzyme-substrate interaction network. Here, we show that catalytic efficiency and mutational effects can be interpreted through enzyme-substrate interaction topology. We developed Interkcat, an interpretable bidirectional cross-attention framework that captures reciprocal coordination between protein residues and substrate atoms. Optimized on a unified benchmark, Interkcat achieves state-of-the-art predictive performance (R2 = 0.701). From its learned representations, we derive an Interaction Topology Score (ITS) that identifies sequence regions statistically enriched for mutation-sensitive sites without explicit structural inputs. We further demonstrate that higher-order topological features distinguish opposing mutational outcomes: lethal mutations disrupt coordinated networks, whereas activity-preserving or enhancing mutations retain sparse, globally organized coupling. These findings establish interaction topology as a unifying principle linking enzyme sequence, catalytic efficiency, and evolutionary perturbation.

q-bio.BM↗

arXiv2026

Adapting Boltz-2 with limited experimental activity data improves early enrichment in virtual screening

Virtual screening aims to prioritize active compounds from large chemical libraries within a limited experimental budget. When applying Boltz-2 to virtual screening, a key challenge is how to use limited experimental data from the target assay to improve the prioritization of active compounds. We investigated whether fine-tuning the Boltz-2 affinity heads with a small number of binary activity labels could improve early enrichment of active compounds in hit discovery. We compared fine-tuning with 40-300 labels in a retrospective evaluation on eight MF-PCBA targets. With 300 activity measurements, fine-tuning increased the number of actives in the top 1% by a geometric mean of 1.77-fold across the eight targets and improved average precision (AP) by 2.14-fold relative to the control without fine-tuning. We also investigated whether rescoring a subset of candidates could retain the improvement in hit recovery by reranking only the top-ranked Boltz-2 candidates with the fine-tuned head. Restricting rescoring to approximately 10% of the evaluation set retained hit recovery comparable to full rescoring. These findings show that affinity-head fine-tuning with limited activity labels improves early enrichment with Boltz-2 and that this benefit can be retained when rescoring a restricted set of candidates.

q-bio.BM↗